Abstract
At that time the introduction of a cancer evolution concept, has failed to revolutionize cancer research. Models of rational reconstruction within an evolution historical frame can be suggested, if an innovative achievement may be denoted for a complex ‘learning process’. Because such models admit a clear normative reference and action-theoretical interpretation; they may be used for narrative presentations. Three main factors emerged as starting point for evolution theoretical considerations, an unmet medical need (systemically pretreated patients with metastatic tumors), a hypothesis-driven vision (the formal pragmatic communication theory) and technological advances to pursue that vision (biomodulatory therapy approaches, clinical proteomics, epigenetics and molecular imaging techniques). An evolution theory allows for virtualizing the engagement to get experiences and decisions (pragmatic virtualization of communication acts) via implementation of non-normative boundary conditions (for example, biomodulatory therapies). The feasibility to virtualize the engagement to get situate experiences about tumor systems and decisions to tailor biomodulatory therapies (communication-derived tumor pathophysiology), the availability of an evolutionarily adapted modeling of cancer (cellular therapy in situ by adaptive therapies) will continue to increase our understanding of tumor pathophysiology and may contribute to an evolution-oriented design of systems biological strategies to diagnose and clinically manage tumor diseases on a novel personalized level. Basic science is getting directly involved in the reconstructive process, even though an approach has been established directed from bedside to bench aimed at implementing clinical practical care (adaptive trial designs) as scientific object in patient care.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Vineis P, Berwick M (2006) The population dynamics of cancer: a Darwinian perspective. Int J Epidemiol 35:1151–1159
Heng HH, Stevens JB, Bremer SW, Liu G, Abdallah BY, Ye CJ (2011) Evolutionary mechanisms and diversity in cancer. Adv Cancer Res 112:217–253
Reichle A (2009) Tumor systems need to be rendered usable for a new action-theoretical abstraction: the starting point for novel therapeutic options. Curr Cancer Ther Rev 5:232–242
Beerenwinkel N, Antal T, Dingli D et al (2007) Genetic progression and the waiting time to cancer. PLoS Comput Biol 3:e225
Gerhart J, Kirschner M (2007) The theory of facilitated variation. Proc Natl Acad Sci USA 104(Suppl 1):8582–8589
Cairns J (1979) Mutation selection and the natural history of cancer. Nature 255(5505):197–200
Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194(4260):23–28
Crespi B, Summers K (2005) Evolutionary biology of cancer. Trends Ecol Evol 20:545–552
Merlo LM, Pepper JW, Reid BJ, Maley CC (2006) Cancer as an evolutionary and ecological process. Nat Rev Cancer 6:924–935
Nowak MA (2006) Five rules for the evolution of cooperation. Science 314:1560–1563
Garcia-Mata R, Boulter E, Burridge K (2001) The ‘invisible hand’: regulation of RHO GTPases by RHOGDIs. Nat Rev Mol Cell Biol 12:493–504
Gatenby RA, Vincent TL (2003) An evolutionary model of carcinogenesis. Cancer Res 63:6212–6220
Grouchy J (1977) Theodore Boveri and the chromosomal theory of oncogenesis. Nouv Rev Fr Hematol Blood Cells 18:1–4
Axelrod R, Axelrod DE, Pienta KJ (2006) Evolution of cooperation among tumor cells. Proc Natl Acad Sci USA 103:13474–13479
Ye CJ, Stevens JB, Liu G et al (2009) Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J Cell Physiol 219:288–300
Pavlicev M, Cheverud JM, Wagner GP (2011) Evolution of adaptive phenotypic variation patterns by direct selection for evolvability. Proc Biol Sci 278:1903–1912
Attolini CS, Michor F (2009) Evolutionary theory of cancer. Ann N Y Acad Sci 1168:23–51
Lin C, Yang L, Tanasa B et al (2009) Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139:1069–1083
Knudson AG, Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–82
Armitage P, Doll R (2004) The age distribution of cancer and a multi-stage theory of carcinogenesis. Int J Epidemiol 33:1174–1179
Radisky DC, Levy DD, Littlepage LE et al (2005) Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436:123–127
Lacoste S, Wiechec E, Dos Santos Silva AG et al (2010) Chromosomal rearrangements after ex vivo Epstein-Barr virus (EBV) infection of human B cells. Oncogene 29:503–515
Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ (2009) Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. J Cell Physiol 220:538–547
Louhelainen J, Szyfter K, Szyfter W, Hemminki K (1997) Loss of heterozygosity and microsatellite instability in larynx cancer. Int J Oncol 10:247–252
Green MR (2008) Senescence: not just for tumor suppression. Cell 134:562–564
Merlo LM, Maley CC (2010) The role of genetic diversity in cancer. J Clin Invest(120):401–403
Jablonka E, Lamb M (2002) Creating bridges or rifts? Developmental systems theory and evolutionary developmental biology Bioessays 24:290–291
Nicholson MJ, Duesberg P (2009) On the karyotypic origin and evolution of cancer cells. Cancer Genet Cytogenet 194:96–110
Desper R, Gascuel O (2004) Theoretical foundation of the balanced minimum evolution method of phylogenetic inference and its relationship to weighted least-squares tree fitting. Mol Biol Evol 21:587–598
Shibata D, Tavare S (2006) Counting divisions in a human somatic cell tree: how, what and why? Cell Cycle 5:610–614
Kim Y (2007) Rate of adaptive peak shifts with partial genetic robustness. Evolution Int J org Evolution 61:1847–1856
Lee HO, Silva AS, Concilio S et al (2011) Evolution of tumor invasiveness: the adaptive tumor microenvironment landscape model. Cancer Res 71:6327–6337
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674
Greaves M (2009) Darwin and evolutionary tales in leukemia. The Ham-Wasserman Lecture. Hematology Am Soc Hematol Educ Program 3–12
Heng HH (2009) The genome-centric concept: resynthesis of evolutionary theory. Bioessays 31:512–525
Califano A (2011) Rewiring makes the difference. Mol Syst Biol 7:463
Goh AM, Coffill CR, Lane DP (2011) The role of mutant p53 in human cancer. J Pathol 223:116–126
Reichle A (2010) Bridging theory and therapeutic practice: from generalized disease models to particular patients. In: From molecular to modular tumor therapy: the tumor microenvironment, vol 3. Springer, pp 3–7. doi:10.1007/978–90-481–9531-2_1
Reichle A, Hildebrandt GC (2009) Principles of modular tumor therapy. Cancer Microenviron 2(Suppl 1):227–237
Ravandi F, Cortes JE, Jones D et al (2010) Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 28:1856–1862
Metzelder S, Wang Y, Wollmer E et al (2009) Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 113:6567–6571
Mahon FX, Rea D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029–1035
Falchi L, Rege-Cambrin G, Fava C et al (2010) Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution. Cancer Genet Cytogenet 199:139–142
Schrattenholz A, Groebe K, Soskic V (2010) Systems biology approaches and tools for analysis of interactomes and multi-target drugs. Methods Mol Biol 662:29–58
Gerber DE, Minna JD (2010) ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 18:548–551
Reichle A, Hildebrandt GC (2008) Systems biology: a therapeutic target for tumor therapy. Cancer Microenviron 1:159–170
Reichle A, Vogelhuber M, Feyerabend S et al (2011) A phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone, and low-dose treosulfan: Combined anti-inflammatory, immunomodulatory, and angiostatic treatment in patients (pts) with castration-refractory prostate cancer (CRPC). J Clin Oncol 29(Suppl):abstr 4599
Emmenegger U et al (2010) The biomodulatory capacities of low-dose metronomic chemotherapy: complex modulation of the tumor microenvironment. In: From molecular to modular tumor therapy: the tumor microenvironment vol 3, part 3. Springer, pp 243–262. doi:10.1007/978–90-481–9531-2_11
Beck IME, Haegemann G, de Bosscher K (2010) Molecular cross-talk between nuclear receptors and nuclear factor-NFkappaB. In: From molecular to modular tumor therapy: the tumor microenvironment, vol 3, part 3. Springer, pp 191–242. doi:10.1007/978–90-481–9531-2_10
Pitteri SJ, Kelly-Spratt KS, Gurley KE et al (2011) Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res 71:5090–5100
Lam LL, Emberly E, Fraser HB, Neumann SM, Chen E, Miller GE, Kobor MS (2012) Factors underlying variable DNA methylation in a human community cohort. Proc Natl Acad Sci USA 109(Suppl 2):17253–60. doi: 10.1073/pnas.1121249109. Epub 2012 Oct 8
Kiessling F, Lederle W (2010) Early detection of systems response: Molecular and functional imaging of angiogenesis. In: Reichle A, (ed) from molecular to modular tumor therapy: the tumor microenvironment. vol 3, part 6. Springer, pp 385–403. doi:10.1007/978–90-481–9531-2_20
Reichle A, Hildebrandt GC (2010) From molecular to modular, from theme-dependent to evolution-adjusted tumor therapy. In: From molecular to modular tumor therapy. the tumor microenvironment, vol 3, part 7. Springer, pp 467–489. doi:10.1007/978–90-481-9531-2_27. 223
Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8:98–101
Chen LL, Blumm N, Christakis NA, Barabasi AL, Deisboeck TS (2009) Cancer metastasis networks and the prediction of progression patterns. Br J Cancer 101:749–758
Coghlin C, Murray GI (2010) Current and emerging concepts in tumour metastasis. J Pathol 222:1–15
Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820–827
Raaijmakers MH, Mukherjee S, Guo S et al (2010) Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464:852–857
Shackleton M, Quintana E, Fearon ER, Morrison SJ (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138:822–829
Zipori D (2004) The nature of stem cells: state rather than entity. Nat Rev Genet 5:873–878
Gatenby RA, Gillies RJ, Brown JS (2011) Of cancer and cave fish. Nat Rev Cancer 11:237–238
Kvinlaug BT, Chan WI, Bullinger L et al (2011) Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res 71:4117–4129
Sottoriva A, Vermeulen L, Tavare S (2011) Modeling evolutionary dynamics of epigenetic mutations in hierarchically organized tumors. PLoS Comput Biol 7:e1001132
Rubin H (2009) Saturation density of skin fibroblasts as a quantitative screen for human cancer susceptibility. Cancer Epidemiol Biomarkers Prev 18:2366–2372
Michor F, Nowak MA, Iwasa Y (2006) Evolution of resistance to cancer therapy. Curr Pharm Des 12:261–271
Reichle A, Hildebrandt GC (2010) To be an object in a biological system: the necessity of a formal-pragmatic communication theory. In: From molecular to modular tumor therapy: the tumor microenvironment, vol 3, part 9. Springer, pp 537–544. doi:10.1007/978–90-481–9531-2_26
Dingli D, Chalub FA, Santos FC, Van SS, Pacheco JM (2009) Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells. Br J Cancer 101:1130–1136
Reichle A, Hildebrandt GC (2010) The comparative uncovering of tumor systems biology by modularly targeting tumor-associated inflammation. In: From molecular to modular tumor therapy: the tumor microenvironment, vol 3, part 4. Springer, pp 287–303. doi:10.1007/978–90-481–9531-9532
Reichle A, Hildebrandt GC (2010) Searching for the ‘metabolism’ of evolution. In: From molecular to modular tumor therapy: the tumor microenvironment, vol 3, part 4. Springer, pp 305–309. doi:10.1007/978–90-481–9531-2_14
Reichle A, Hildebrandt GC (2010) Uncovering tumor systems biology by biomodulatory therapy strategies. In: From molecular to modular tumor therapy. The tumor microenvironment, vol 3, part 4. Springer, pp 287–303. doi:10.1007/978–90-481–9531-2_13
Wagner GP, Pavlicev M, Cheverud JM (2007) The road to modularity. Nat Rev Genet 8:921–931
Hartwell LH, Hopfield JJ, Leibler S, Murray AW (1999) From molecular to modular cell biology. Nature 402:C47–C52
Heinz S, Benner C, Spann N et al (2010) Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 38:576–589
Weber BN, Chi AW, Chavez A et al (2011) A critical role for TCF-1 in T-lineage specification and differentiation. Nature 476:63–68
Puglisi R, Maccari I, Pipolo S et al (2012) The nuclear form of glutathione peroxidase 4 is associated with sperm nuclear matrix and is required for proper paternal chromatin decondensation at fertilization. J Cell Physiol 227:1420–1427
Spemann H, Mangold H (2001) Induction of embryonic primordia by implantation of organizers from a different species. 1923. Int J Dev Biol(45):13–38
Kar G, Gursoy A, Keskin O (2009) Human cancer protein-protein interaction network: a structural perspective. PLoS Comput Biol 5:e1000601
Kitano H (2003) Cancer robustness: tumour tactics. Nature 426:123
Feret J, Danos V, Krivine J, Harmer R, Fontana W (2009) Internal coarse-graining of molecular systems. Proc Natl Acad Sci USA 106:6453–6458
Harmer R, Danos V, Feret J, Krivine J, Fontana W (2010) Intrinsic information carriers in combinatorial dynamical systems. Chaos 20:037108
Grauer O, Hau P (2010) Could be systems-directed therapy approaches promising in glioblastoma patients? In: From molecular to modular tumor therapy: the tumor microenvironment, vol 3, part 2. Springer, pp 133–157. doi:10.1007/978–90-481–9531-2_8
Wagner GP, Kenney-Hunt JP, Pavlicev M, Peck JR, Waxman D, Cheverud JM (2008) Pleiotropic scaling of gene effects and the cost of complexity. Nature 452:470–472
Reichle A, Vogt T, Hildebrandt GC (2010) A methodological approach to personalized therapies in metastatic cancer. In: Reichle A, (ed) from molecular to modular tumor therapy: the tumor microenvironment, vol 3, part 8. Springer, pp 507–33. doi:10.1007/978–90-481-9531-2_25
Trosko JE, Chang CC (1978) Environmental carcinogenesis: an integrative model. Q Rev Biol(53):115–141
Vineis P, Xun W (2009) The emerging epidemic of environmental cancers in developing countries. Ann Oncol 20:205–212
Lefevre S, Knedla A, Tennie C et al (2009) Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 15:1414–1420
Rodig SJ, Ouyang J, Juszczynski P et al (2008) AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res 14:3338–3344
Bacac M, Provero P, Mayran N, Stehle JC, Fusco C, Stamenkovic I (2006) A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival. PLoS One 1:e32
Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 303:1960–1964
Chabner BA, Roberts TG Jr (2005) Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 5:65–72
Markert CL (1968) Neoplasia: a disease of cell differentiation. Cancer Res 28:1908–1914
Hagemann T, Lawrence T, McNeish I et al (2008) “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med 205:1261–1268
Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532
Chu D (2011) Complexity: against systems. Theory Biosci 130:229–245
Oprea TI, Bauman JE, Bologa CG et al (2011) Drug Repurposing from an Academic Perspective. Drug Discov Today Ther Strateg 8:61–69
Dobzhansky T (1973) Nothing in biology makes sense except in the light of evolution. The American Biology Teacher 35:125–129. http://www.2think.org/dobzhansky.shtml
Chindelevitch L, Ziemek D, Enayetallah A, Randhawa R, Sidders B, Brockel C, Huang ES (2012) Causal reasoning on biological networks: interpreting transcriptional changes. Bioinformatics 28(8):1114–1121
Ewald PW, Swain Ewald HA (2013) Toward a general evolutionary theory of oncogenesis. Evol Appl 6(1):70–81
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Reichle, A., Hildebrandt, G. (2013). Evolution Theory: Its Practical Relevance for Understanding Tumor Development and Specifying Tumor Therapy. In: Reichle, A. (eds) Evolution-adjusted Tumor Pathophysiology:. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6866-6_12
Download citation
DOI: https://doi.org/10.1007/978-94-007-6866-6_12
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-6865-9
Online ISBN: 978-94-007-6866-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)